These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 12435873)

  • 1. Intravenous iron: the iatrogenic kick to lose control over oxygen?
    Deicher R; Hörl WH
    Kidney Blood Press Res; 2002; 25(5):284-8. PubMed ID: 12435873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron in the treatment of anemia in dialysis patients: an important support to erythropoietin.
    Gallieni M
    Int J Artif Organs; 1998 Nov; 21(11):681-6. PubMed ID: 9894741
    [No Abstract]   [Full Text] [Related]  

  • 3. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 4. Iron supplementation in renal anemia.
    Fishbane S
    Semin Nephrol; 2006 Jul; 26(4):319-24. PubMed ID: 16949471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment with high dose of intravenous iron increases mortality and hospitalization in hemodialysis].
    Fernández-Gallego J; Martín Reyes G; Valera A; Toledo R
    Nefrologia; 2004; 24(1):87-8. PubMed ID: 15083966
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravenous iron and anaemia in haemodialysis patients.
    Shaldon S
    Nephron; 1998 Dec; 80(4):485. PubMed ID: 9832655
    [No Abstract]   [Full Text] [Related]  

  • 7. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment with high-dose intravenous iron increases mortality and hospitalization in hemodialysis. The basic idea is more important than the style].
    Fernández-Gallego J
    Nefrologia; 2005; 25(3):340. PubMed ID: 16053019
    [No Abstract]   [Full Text] [Related]  

  • 9. Anemia management and mortality risk in incident hemodialysis patients.
    Auerbach M
    JAMA; 2010 Jul; 304(1):41-2; author reply 42-3. PubMed ID: 20606145
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemic of iron overload in dialysis population caused by intravenous iron products: a plea for moderation.
    Vaziri ND
    Am J Med; 2012 Oct; 125(10):951-2. PubMed ID: 22795817
    [No Abstract]   [Full Text] [Related]  

  • 12. Introduction to "A road map for intravenous iron and anemia management: preparing for the future".
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S1-4. PubMed ID: 19010256
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of intravenous iron in hemodialysis patients.
    Li X; Kshirsagar AV; Brookhart MA
    Hemodial Int; 2017 Jun; 21 Suppl 1(Suppl 1):S93-S103. PubMed ID: 28370957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receipt of Intravenous Iron and Clinical Outcomes among Hemodialysis Patients Hospitalized for Infection.
    Ishida JH; Marafino BJ; McCulloch CE; Dalrymple LS; Dudley RA; Grimes BA; Johansen KL
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1799-805. PubMed ID: 26416943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous iron therapy in peritoneal dialysis patients: short-term efficacy and long-term issues.
    Zager RA
    Clin J Am Soc Nephrol; 2006 May; 1(3):353-5. PubMed ID: 17699230
    [No Abstract]   [Full Text] [Related]  

  • 16. Oxidative stress, renal anemia, and its therapies: is there a link?
    Căpuşă C; Mircescu G
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S71-6. PubMed ID: 20797576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron.
    Kapoian T
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S21-8. PubMed ID: 19010258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of parenteral iron on inflammation and the myocardium in hemodialysis patients.
    Sood MM; Oudit GY; Mohammadi H; Huang H; Lok CE
    Hemodial Int; 2008 Jul; 12(3):362-8. PubMed ID: 18638094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
    Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
    Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous iron, inflammation, and oxidative stress: is iron a friend or an enemy of uremic patients?
    Garneata L
    J Ren Nutr; 2008 Jan; 18(1):40-5. PubMed ID: 18089442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.